Table 2 Gene ontology analysis of genes within 50 kb of differentially methylated positions from each cross-diagnosis comparison

BENPORATH_SUZ12_TARGETS

1038

37

0.0356

1.98E-22

BENPORATH_ES_WITH_H3K27ME3

1118

38

0.034

2.60E-22

BENPORATH_EED_TARGETS

1062

37

0.0348

4.29E-22

GO_NEURON_DIFFERENTIATION

874

29

0.0332

6.78E-17

GO_NEUROGENESIS

1402

35

0.025

2.00E-16

BENPORATH_PRC2_TARGETS

652

25

0.0383

4.04E-16

GO_CELL_DEVELOPMENT

1426

33

0.0231

1.36E-14

MIKKELSEN_NPC_HCP_WITH_H3K27ME3

341

18

0.0528

2.97E-14

MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3

1069

28

0.0262

8.47E-14

MIKKELSEN_MEF_HCP_WITH_H3K27ME3

590

20

0.0339

3.87E-12

GO_NEUROGENESIS

1402

18

0.0128

1.35E-09

GO_CELL_PROJECTION

1786

20

0.0112

1.52E-09

MEISSNER_NPC_HCP_WITH_H3_UNMETHYLATED

536

12

0.0224

2.32E-09

BENPORATH_SUZ12_TARGETS

1038

15

0.0145

7.80E-09

MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3

1069

15

0.014

1.15E-08

BENPORATH_ES_WITH_H3K27ME3

1118

15

0.0134

2.08E-08

GO_CELL_DEVELOPMENT

1426

16

0.0112

7.88E-08

BENPORATH_EED_TARGETS

1062

14

0.0132

7.96E-08

GO_CELL_PROJECTION_PART

946

13

0.0137

1.50E-07

GSE40443_INDUCED_VS_TOTAL_TREG_UP

200

7

0.035

3.03E-07

GO_INTRINSIC_COMPONENT_OF_PLASMA_MEMBRANE

1649

15

0.0091

7.16E-08

GO_CELL_SURFACE

757

10

0.0132

4.97E-07

GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS

975

11

0.0113

6.04E-07

GO_CELL_PROJECTION

1786

14

0.0078

1.22E-06

BIOCARTA_LAIR_PATHWAY

17

3

0.1765

2.91E-06

GO_ALPHA_ACTININ_BINDING

21

3

0.1429

5.66E-06

BLALOCK_ALZHEIMERS_DISEASE_DN

1237

11

0.0089

5.94E-06

GO_NEURON_PART

1265

11

0.0087

7.34E-06

GO_REGULATION_OF_TRANSPORT

1804

13

0.0072

7.65E-06